Media & Press

  • Phebra Receives TGA Authorisation for Manufacture of Critical Care Medicines for TGA Trials
  • Phebra acquires equity stake in UK Specialty Hospital Pharma company Flexipharm Austrading
  • Phebra Plant Expansion Wins NSW Industry Award 2021
  • Phebra Announces New Licensing Agreement with Medsenic for the Development of its Oral Arsenic Trioxide Formulation in the Treatment of Chronic Graft-Versus-Host and Autoimmune Diseases
  • Final Results of Bioavailability Study of Phebra’s Oral Arsenic Capsule
  • Phebra Canada’s Milestones in Delivery of Critical Medicines
  • Phebra Secures Supply Of Critical Medicines With Sydney Manufacturing Plant Expansion
  • Phebra Signs International Distribution Agreement For Manufacture And Supply Of A New Pharmaceutical For Treatment Of Duchenne Muscular Dystrophy
  • World-First Trial To Test Benefit Of Intravenous Zinc In COVID-19 Fight
  • Phebra Establishes New Subsidiary In Canada And Announces Marketing Approval For IV Arsenic Trioxide Solution